Abiopharma

🔍 Smith Jeffrey T L (Executive)

Company: Zymeworks Inc. (ZYME)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Common Stock (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: false | shares_owned_after: 28,890.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 10,538 shares of Common Stock at $25.0969 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 18,352.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 20,000 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-05 | Code: M | equity_swap_involved: false | shares_owned_after: 20,000.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5

Footnotes:

• F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2024.
• F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
• F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.715 to $25.84, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
• F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
• F5: The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024.